Stockscreener 앱 받기
0.2751
7.54%
0.0193
시간 외 거래:
.28
0.0049
+1.78%
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
Sangamo targets summer 2026 for Fabry BLA submission while advancing neurology pipeline and partner talks - MSN
SGMO News | SANGAMO THERAPEUTICS INC (NASDAQ:SGMO) - ChartMill
Fabry Disease Market Set for Robust Growth by 2034, Driven by Gene Therapy Breakthroughs and Expanding Pipeline from Sangamo, Sanofi, Amicus & Emerging Innovators | DelveInsight - Barchart.com
HC Wainwright Has Negative Forecast for SGMO FY2026 Earnings - MarketBeat
Analyst Calls: Will Sangamo Therapeutics Inc benefit from geopolitical trendsPortfolio Risk Summary & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
SGMO SEC FilingsSangamo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Sangamo (NASDAQ: SGMO) awards 225,000 stock options to accounting chief - Stock Titan
Sangamo (SGMO) CEO Sandy Macrae receives 2.5M stock option grant at $0.2601 - Stock Titan
Sangamo (NASDAQ: SGMO) CLO awarded 800,000 options at $0.2601 - Stock Titan
Equities Analysts Issue Forecasts for SGMO FY2028 Earnings - MarketBeat
Sangamo Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SGMO) 2026-04-02 - Seeking Alpha
Sangamo Therapeutics Nears Key Milestone with Accelerated FDA Pathway for Fabry Disease Therapy - aktiencheck.de
Sangamo Therapeutics Faces Rising Trade Policy Risks, Higher Costs and Global Growth Uncertainty - TipRanks
RBC Capital Maintains Sangamo Therapeutics(SGMO.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Sangamo Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Sangamo: Q4 Earnings Snapshot - theheraldreview.com
Sangamo Reports Pipeline Progress And Wider FY25 Loss, Stock Down 17% Overnight - RTTNews
Sangamo Therapeutics (SGMO) Q4 Loss Highlights Deep TTM Deficit Challenging Bullish Profitability Hopes - Sahm
Sangamo Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Sangamo Therapeutics Inc (SGMO) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus
Sangamo Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Sangamo’s Q4 2025 earnings miss, stock fluctuates By Investing.com - Investing.com Australia
Sangamo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
SGMO Faces Uncertainty Without Additional Funding - GuruFocus
Sangamo Therapeutics | 8-K: SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS - moomoo.com
Sangamo (SGMO) Reports Robust Revenue Growth and Pipeline Progre - GuruFocus
Sangamo Therapeutics (NASDAQ:SGMO) Releases Quarterly Earnings Results, Misses Expectations By $0.12 EPS - MarketBeat
Earnings call transcript: Sangamo’s Q4 2025 earnings miss, stock fluctuates - Investing.com
Sangamo Therapeutics Q4 Loss Is Unchanged, Revenue Climbs - Moomoo
Sangamo Therapeutics earnings missed by $0.10, revenue fell short of estimates - Investing.com Canada
Q4 2025 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus
BRIEF-Sangamo Therapeutics Q4 EPS USD -0.11 - TradingView
Sangamo Therapeutics, Inc. Reports Unaudited consolidated Impairment Charges for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Sangamo Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnin - Benzinga
Sangamo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Sangamo Therapeutics, Inc. Trade Ideas — LSX:936386 - tradingview.com
Sangamo Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Gains Report: Is Sangamo Therapeutics Inc a strong growth stockEarnings Recap Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
If You Invested $1,000 in Sangamo Therapeutics Inc (SGMO) - Stock Titan
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call - The Manila Times
Sangamo will post 2025 results after the close on March 30 - Stock Titan
Sangamo Therapeutics (SGMO) NASDAQ US 18 Mar 2026: Market closed, earnings tonight - Meyka
EPS Watch: Does Sangamo Therapeutics Inc have consistent dividend growth2026 PostEarnings & Real-Time Buy Signal Notifications - baoquankhu1.vn
Sangamo seeks accelerated US approval of gene therapy for Fabry - Fabry Disease News
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Sangamo Biosciences (SGMO) and Protalix (PLX) - The Globe and Mail
Sangamo Therapeutics (SGMO) shares stabilize amid recent key pipeline update - MSN
Fabry Disease Market: Rapid Growth & Investment Outlook to 2034 – DelveInsight | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart
Sangamo (SGMO) Advances FDA Submission for Gene Therapy Approval - GuruFocus
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - The Manila Times
2.69%
0.25%
자본화:
|
볼륨(24시간):